|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hong SM, Park JY, Hruban RH and Goggins M:
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med.
135:716–727. 2011.PubMed/NCBI
|
|
3
|
Wolffe AP and Matzke MA: Epigenetics:
Regulation through repression. Science. 286:481–486. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Singal R and Ginder GD: DNA methylation.
Blood. 93:4059–4070. 1999.PubMed/NCBI
|
|
5
|
Esteller M: Cancer epigenomics: DNA
methylomes and histone-modification maps. Nat Rev Genet. 8:286–298.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merlo A, Herman JG, Mao L, Lee DJ,
Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island
methylation is associated with transcriptional silencing of the
tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med.
1:686–692. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiang T, Li L, Yin X, Yuan C, Tan C, Su X,
Xiong L, Putti TC, Oberst M, Kelly K, et al: The ubiquitin
peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis
through stabilizing p53 and is frequently silenced in breast
cancer. PLoS One. 7:e297832012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Ying J, Tong X, Zhong L, Su X, Xiang
T, Shu X, Rong R, Xiong L, Li H, et al: Epigenetic identification
of receptor tyrosine kinase-like orphan receptor 2 as a functional
tumor suppressor inhibiting β-catenin and AKT signaling but
frequently methylated in common carcinomas. Cell Mol Life Sci.
71:2179–2192. 2014. View Article : Google Scholar
|
|
9
|
Redies C, Vanhalst K and Roy F:
Delta-Protocadherins: Unique structures and functions. Cell Mol
Life Sci. 62:2840–2852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morishita H and Yagi T: Protocadherin
family: Diversity, structure, and function. Curr Opin Cell Biol.
19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu JS, Koujak S, Nagase S, Li CM, Su T,
Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8,
the human homolog of PAPC, is a candidate tumor suppressor of
breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu X, Sui X, Li L, Huang X, Rong R, Su X,
Shi Q, Mo L, Shu X, Kuang Y, et al: Protocadherin 17 acts as a
tumour suppressor inducing tumour cell apoptosis and autophagy, and
is frequently methylated in gastric and colorectal cancers. J
Pathol. 229:62–73. 2013. View Article : Google Scholar
|
|
13
|
Lv J, Zhu P, Yang Z, Li M, Zhang X, Cheng
J, Chen X and Lu F: PCDH20 functions as a tumour-suppressor gene
through antagonizing the Wnt/β-catenin signalling pathway in
hepatocellular carcinoma. J Viral Hepat. 22:201–211. 2015.
View Article : Google Scholar
|
|
14
|
Li Z, Chim JC, Yang M, Ye J, Wong BC and
Qiao L: Role of PCDH10 and its hypermethylation in human gastric
cancer. Biochim Biophys Acta. 1823:298–305. 2012. View Article : Google Scholar
|
|
15
|
Zhong X, Zhu Y, Mao J, Zhang J and Zheng
S: Frequent epigenetic silencing of PCDH10 by methylation in human
colorectal cancer. J Cancer Res Clin Oncol. 139:485–490. 2013.
View Article : Google Scholar
|
|
16
|
Tang X, Yin X, Xiang T, Li H, Li F, Chen L
and Ren G: Protocadherin 10 is frequently downregulated by promoter
methylation and functions as a tumor suppressor gene in non-small
cell lung cancer. Cancer Biomark. 12:11–19. 2013.PubMed/NCBI
|
|
17
|
Ying J, Li H, Seng TJ, Langford C,
Srivastava G, Tsao SW, Putti T, Murray P, Chan AT and Tao Q:
Functional epigenetics identifies a protocadherin PCDH10 as a
candidate tumor suppressor for nasopharyngeal, esophageal and
multiple other carcinomas with frequent methylation. Oncogene.
25:1070–1080. 2006. View Article : Google Scholar
|
|
18
|
Redston MS, Caldas C, Seymour AB, Hruban
RH, da Costa L, Yeo CJ and Kern SE: p53 mutations in pancreatic
carcinoma and evidence of common involvement of homocopolymer
tracts in DNA microdeletions. Cancer Res. 54:3025–3033.
1994.PubMed/NCBI
|
|
19
|
Yi JM, Guzzetta AA, Bailey VJ, Downing SR,
Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A,
Wolfgang C, et al: Novel methylation biomarker panel for the early
detection of pancreatic cancer. Clin Cancer Res. 19:6544–6555.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roperch JP, Incitti R, Forbin S, Bard F,
Mansour H, Mesli F, Baumgaertner I, Brunetti F and Sobhani I:
Aberrant methylation of NPY, PENK, and WIF1 as a promising marker
for blood-based diagnosis of colorectal cancer. BMC Cancer.
13:5662013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balgkouranidou I, Matthaios D,
Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis
K, Chelis L, Trypsianis G, Chatzaki E, et al: Prognostic role of
APC and RASSF1A promoter methylation status in cell free
circulating DNA of operable gastric cancer patients. Mutat Res.
778:46–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schutte M, Hruban RH, Geradts J, Maynard
R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff
I, Schmiegel W, et al: Abrogation of the Rb/p16 tumor-suppressive
pathway in virtually all pancreatic carcinomas. Cancer Res.
57:3126–3130. 1997.PubMed/NCBI
|
|
23
|
Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN,
Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al: Methylation of
protocadherin 10, a novel tumor suppressor, is associated with poor
prognosis in patients with gastric cancer. Gastroenterology.
136:640–51.e1. 2009. View Article : Google Scholar
|
|
24
|
Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC,
Tzeng ST, Chang CY, Lai YC, Yen SJ, Yu SL, et al: Protocadherin 10
suppresses tumorigenesis and metastasis in colorectal cancer and
its genetic loss predicts adverse prognosis. Int J Cancer.
135:2593–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q
and Chen J: PCDH10 inhibits cell proliferation of multiple myeloma
via the negative regulation of the Wnt/β-catenin/BCL-9 signaling
pathway. Oncol Rep. 34:747–754. 2015.PubMed/NCBI
|
|
26
|
Li Z, Yang Z, Peng X, Li Y, Liu Q and Chen
J: Nuclear factor-κB is involved in the protocadherin-10-mediated
pro-apoptotic effect in multiple myeloma. Mol Med Rep. 10:832–838.
2014.PubMed/NCBI
|
|
27
|
Degterev A and Yuan J: Expansion and
evolution of cell death programmes. Nat Rev Mol Cell Biol.
9:378–390. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drel' VR, Shymans'kyĭ IO, Sybirna NO and
Velykyĭ MM: Role of PARP and protein poly-ADP-ribosylation process
in regulation of cell functions. Ukr Biokhim Zh. 83:5–34. 2011.
|
|
30
|
Fuchs Y and Steller H: Programmed cell
death in animal development and disease. Cell. 147:742–758. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
